Advertisement
U.S. markets closed

Qiagen N.V. (QIA.DE)

XETRA - XETRA Delayed Price. Currency in EUR
40.62+0.51 (+1.28%)
At close: 05:43PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close40.10
Open40.20
Bid40.56 x 48300
Ask40.56 x 51100
Day's Range40.19 - 40.70
52 Week Range33.75 - 44.81
Volume512,459
Avg. Volume620,183
Market Cap9.074B
Beta (5Y Monthly)0.41
PE Ratio (TTM)29.01
EPS (TTM)1.40
Earnings DateN/A
Forward Dividend & Yield1.18 (2.94%)
Ex-Dividend DateJan 30, 2024
1y Target Est47.90
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for QIA.DE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

      Joint educational initiative to focus on Interferon Gamma Release Assay (IGRA) benefits for healthcare providers // Updated U.S. CDC guidelines mandate IGRA testing for individuals aged 2 and older from high‑TB incidence countries, as part of U.S. immigrant visa medical exam // QIAGEN to host global, CPD-accredited event on March 21, just before World TB Day, focusing on TB infection screening, preventive therapy and challenges of high-risk groupsGermantown, Maryland, and Venlo, the Netherlands,

    • Zacks

      Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?

      Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    • GlobeNewswire

      QIAGEN announces Form 20-F annual report filing for 2023 results

      Venlo, the Netherlands, March 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here. QIAGEN will provide printed copies of the 2023 Annual Report to shareholders free of charge upon request. To obtain a p